Poziotinib
Poziotinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against receptor tyrosine-protein kinase erbB-4, receptor tyrosine-protein kinase erbB-2, and epidermal growth factor receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | 1 | 6 | 1 | — | — | 7 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 5 | — | — | — | 6 |
| Neoplasms | D009369 | C80 | 2 | 1 | — | — | — | 3 | |
| Squamous cell carcinoma of head and neck | D000077195 | — | 2 | — | — | — | 2 | ||
| Adenocarcinoma of lung | D000077192 | — | 2 | — | — | — | 2 | ||
| Esophageal squamous cell carcinoma | D000077277 | — | 1 | — | — | — | 1 | ||
| Head and neck neoplasms | D006258 | — | 1 | — | — | — | 1 | ||
| Colorectal neoplasms | D015179 | — | 1 | — | — | — | 1 | ||
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | 1 | |
| Lung neoplasms | D008175 | C34.90 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 2 | — | — | — | — | 2 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | POZIOTINIB |
| INN | poziotinib |
| Description | Poziotinib (NOV120101, HM781-36B) is a drug in development by Hanmi Pharmaceutical (in South Korea), Luye Pharma (China), and Spectrum Pharmaceuticals (rest of world) for various cancers.
|
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C=CC(=O)N1CCC(Oc2cc3c(Nc4ccc(Cl)c(Cl)c4F)ncnc3cc2OC)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 1092364-38-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545154 |
| ChEBI ID | — |
| PubChem CID | 25127713 |
| DrugBank | DB12114 |
| UNII ID | OEI6OOU6IK (ChemIDplus, GSRS) |
Target
Agency Approved
ERBB4
ERBB4
ERBB2
ERBB2
EGFR
EGFR
Organism
Homo sapiens
Gene name
ERBB4
Gene synonyms
HER4
NCBI Gene ID
Protein name
receptor tyrosine-protein kinase erbB-4
Protein synonyms
avian erythroblastic leukemia viral (v-erb-b2) oncogene homolog 4, human epidermal growth factor receptor 4, p180erbB4, Proto-oncogene-like protein c-ErbB-4, Tyrosine kinase-type cell surface receptor HER4, v-erb-a erythroblastic leukemia viral oncogene homolog 4, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4
Uniprot ID
Mouse ortholog
Erbb4 (13869)
receptor tyrosine-protein kinase erbB-4 (Q61527)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 491 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more